What Is CJC-1295 no DAC?
CJC-1295 without DAC — commonly called Modified GRF 1-29 — is a 29-amino-acid fragment of GHRH modified at positions 2, 8, 15, and 27 to resist enzymatic degradation. Unlike its DAC-bearing counterpart, it carries no albumin-binding complex, retaining a short half-life of approximately 30 minutes that produces a sharp, transient spike in GH secretion before rapid clearance.
Why Pulsatility Matters
Natural GH secretion is fundamentally pulsatile — the pituitary releases GH in discrete bursts, particularly during deep sleep and post-exercise. Continuous GH elevation (as produced by the DAC version) can desensitize pituitary receptors over time. Modified GRF 1-29 preserves pulsatile architecture, which some researchers consider more physiologically appropriate and potentially less prone to receptor downregulation with extended protocols.
Common Research Combinations
CJC-1295 no DAC is frequently combined with GHRP peptides such as Ipamorelin or GHRP-6. The rationale is synergistic: GHRH analogs prime and amplify the somatotroph pulse while GHRPs suppress somatostatin, the GH-inhibiting peptide. The combination can produce larger, cleaner GH pulses than either compound alone.
Comparison with DAC Version
Researchers choose the no-DAC form when pulse fidelity and natural GH rhythm preservation are the priority. They choose the DAC form when sustained baseline GH elevation and dosing convenience (once or twice weekly) are preferred.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Long-term Safety Profile of Modified GRF Analogs (2015)
Animal model | 6 months | Daily administration - Comparative Analysis: CJC-1295 vs Native GHRH (2010)
In vitro + Human | Various doses | Receptor binding assays - Growth Hormone Pulsatility with Mod GRF 1-29 (2008)
Human | 100mcg 3x daily | 30 days | 24 subjects - Pharmacokinetics of Modified GRF(1-29) in Healthy Adults (2006)
Human | 100-200mcg | Single dose | 12 subjects - The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Dominikowski A, Rękoś Z, Olejarz M, 2026, Front Endocrinol (Lausanne)